Helix BioPharma Corp.: Helix Biopharma Corp. Announces Fiscal 2021 First Quarter Results
Helix BioPharma Corp.: Helix Biopharma Corp. Announces Fiscal 2021 First Quarter Results Helix" or the " Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced its fiscal 2021 first quarter results for the period ending October 31, 2020. OVERVIEW The Company reported a net loss and total comprehensive loss of $222,000 for the three-month period ended October 31, 2020 (2019 - $2,214,000). Net loss and comprehensive loss for the three-month period ending October 31, ...